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Hematopoietic stem and progenitor cells contribute to allergic inflammation. Pro-
inflammatory cytokines that are generated following allergen challenge can impact the
differentiation of hematopoietic progenitor cells leading to increased production of effector
cells such as eosinophils and basophils, which are key cells involved in the pathogene-
sis of allergic airway inflammation. Homing of stem cells to the lungs is associated with
inflammatory and remodeling changes in asthmatics. Factors that modulate the differenti-
ation and increased migration of stem cells to the site of inflammation in asthma remain
to be defined. Stem cells can mature at the site of inflammation in response to inflam-
matory mediators and other components in the milieu. While the available data suggest
that hematopoietic cells traffic to target tissues, the molecular factors underlying in situ
differentiation have yet to be specified. Here, we critically evaluate the potential role of
hematopoietic progenitors in contributing to the increased immune cell infiltrate in allergic
asthma and the factors that drive their differentiation.
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INTRODUCTION
Asthma is a chronic inflammatory disease of the airways character-
ized by infiltration of immune cells, hypersensitivity, bronchocon-
striction, airway obstruction, and airway remodeling (1). One of
the most common types of asthma is allergic asthma. Upon ini-
tial exposure to allergens, the antigen is phagocytized by mucosal
dendritic cells (DCs), which will then travel to regional draining
lymph nodes and present the antigen to naive helper T cells (Th0).
The mechanisms underlying the differentiation of Th0 to type-2
helper T (Th2) cells, the predominant cells found in allergic air-
way inflammation, are not well understood. It is hypothesized that
the environment of the lymph node as well as cytokines released
by activated DCs, cause the differentiation into a Th2 cell (2, 3).
The Th2 cells then travel back to the bronchial mucosa where they
can drive class switching and IgE production by plasma cells at
the site of allergic inflammation through secretion of IL-4, IL-5,
and IL-13 (4). IgE binds primarily to the Fcε receptor I (FcεRI)
on mast cells and basophils in the airway. This sensitization event
primes the airway tissue, so that upon secondary exposure to an
allergen, receptor cross-linking on mast cells and basophils causes
release of their cellular contents consisting of major basic protein,
histamine, prostaglandins, and leukotrienes, which cause bron-
choconstriction and epithelial cell damage. Chemokines released
by these cells recruit other immune cells, including macrophages
and neutrophils, which release their granular products to further
exaggerate inflammation and tissue damage (3, 5, 6).
Differentiation of hematopoietic stem/progenitor (HSPCs)
into different immune cells in the presence of locally ele-
vated cytokines within the lung tissue can provide a continuing
source of inflammation and change in structural cells (7, 8).
Allergen-induced increases in CD34+ HSPCs in the bone mar-
row and airways suggest that a component of the pathophysiology
of allergic asthma involves trafficking of hematopoietic stem cells
from the bone marrow to the lung. The observation that progen-
itor cells are responsive to specific cytokines prompted us to look
at the differentiation and migration of stem cells and their contri-
bution in allergic asthma. The focus of this review is to evaluate
components of HSPCs cell differentiation and the identification
of these cells in the promotion and amplification of the allergic
asthmatic response in the lung. We will also address the potential
therapeutic targets in controlling differentiation and homing of
hematopoietic stem and progenitor cells.
HEMATOPOIETIC STEM CELLS
Hematopoietic progenitors are defined as undifferentiated
pluripotent stem cells capable of self-renewal and differentiation
into all blood cell types. Hematopoietic stem cells circulate in the
bloodstream under steady-state conditions (9). CD34, the marker
of hematopoietic stem cells, is highly expressed on the progeni-
tor cells, decreases with cell maturation, and is lost fully on mature
cells (10). CD45 is also expressed on hematopoietic cells and assists
in bone marrow egress and tissue migration (11, 12).
Stem/progenitor cells have been isolated and many studies
have defined the role of HSPCs in allergic diseases. During
hematopoiesis, hematopoietic stem cells differentiate into mul-
tipotent progenitor cells expressing CD34. The multipotent prog-
enitor cells can further differentiate into the common lymphoid
progenitor or the common myeloid progenitor. Both of these com-
mon progenitor cell types further differentiate into downstream
progenitor cell types before finally differentiating into terminally
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Table 1 | Classification and characteristics of stem/progenitor cell markers: reports examining the homing and differentiation of HSPCs utilize
different markers and starting source materials.
Stem/progenitor markers Source Reference
Forward scatter low, side scatter low, CD34+/CD45dull Human cord blood and peripheral blood Punia et al. (8)
Sca-1+, c-kit+ Human bone marrow and peripheral blood Doyle et al. (14)
Side scatter low, CD34+/CD45dull Human bone marrow Sehmi et al. (15)
Monocyte depleted, CCR3+ CD34+ Human cord blood Lamkhioued et al. (16)
CD45.2+, Lin−, c-kit+ Mouse thoracic duct and bone marrow Massberg, et al. (17)
CD34+, CD3−, CD10−, CD14−, CD19−, CD20−, CD40−, CD56−,
CD83−, IL-5R−, FCεRI−
Human peripheral blood and sputum Allakhverdi et al. (9)
CD34+/CD45+ Mouse BAL and lung tissue Southam et al. (18)
Lin–Sca-1+c-kit+ Mouse bone marrow Dyer et al. (19)
CD34+, hCD3−, hCD4−, hCD8−, hCD19−, hCD56−, CD38− Human cord blood Takagi et al. (20)
differentiated blood cell types. While most studies utilize CD34
expressing cells as HSPCs-derived cells, it is important to realize
that CD34 is expressed on a number of different progenitor cells
in the hematopoietic lineage in addition to hematopoietic stem
cells (13). The majority of studies investigating the migration of
hematopoietic stem cell do not distinguish between hematopoietic
stem cells or hematopoietic progenitor cells (Table 1). Therefore,
in the following discussion these cells will be referred to as a
combined cell population of HSPCs.
Differentiation of hematopoietic stem cells proceeds in the
bone marrow under the influence of resident stromal cells and
growth factors to which stem cells are responsive. Hematopoietic
stem cells or hematopoietic progenitor cells can leave the bone
marrow niche as a requirement for recruitment in response to
stromal cell-derived factor 1α (SDF-1α) (21).
The receptors important in the transmigration of HSPCs are
C–X–C chemokine receptor type 4 (CXCR4) and C–C chemokine
receptor type 3 (CCR3). CXCR4 is a chemokine receptor for
SDF-1α (CXCL12). CXCR4 is expressed on hematopoietic and
lymphopoietic cells and responds to SDF-1α, which is expressed
in the bone marrow, lungs, liver, and lymph nodes. CCR3 is highly
expressed on eosinophils and basophils, but is also expressed on
T-helper cells, mast cells, airway epithelial cells, as well as in prog-
enitor cells (Table 2). This receptor binds and responds to a variety
of chemokines, including eotaxin (CCL11), eotaxin-3 (CCL26),
MCP-3 (CCL7), MCP-4 (CCL13), and regulated on activation,
normal T cell expressed and secreted (RANTES or CCL5) (22).
Other ligands expressed on HSPCs include P-selectin glycoprotein
ligand 1 (PSGL-1) and very late antigen-4 (VLA-4) which bind to
P-selectin and VCAM-1 located on endothelial cells at the site of
entry, respectively (23) (Table 2). While these factors are impor-
tant for homing to the bone marrow, as previously reviewed (24,
25), the following evidence suggests the involvement of HSPCs in
the migration to sites of inflammation using the same cytokines,
chemokines, and growth factors.
HSPCs IN ALLERGY AND ASTHMA
Growth factors and pro-inflammatory cytokines contribute to the
differentiation of HSPCs in allergic diseases, including asthma,
Table 2 | List of cell types and the presence of receptors and their
ligands.
Cell type Receptor Ligand
Hematopoietic stem cells CXCR4 SDF-1α (CXCL12)
Lymphocytes
Eosinophils Eotaxin (CCL11)
Basophils Eotaxin-3 (CCL26)
T-helper cells CCR3 MCP-3 (CCL7)
Progenitor cells MCP-4 (CCL13)
RANTES (CCL5)
Hematopoietic stem cells c-Kit SCF
Leukocytes E-selectin PSGL
Endothelial cells Sialylated carbohydrates
Leukocytes P-selectin PSGL
Endothelial cells
and can occur in both the bone marrow and locally at the site
of inflammation (9, 15, 18). The importance of hematopoietic
stem cells in the initiation and onset of allergy and asthma was
demonstrated when bone marrow cells from an allergic donor
were transferred to a recipient with no known allergies. This
resulted in the recipient with the synthesis of serum IgE levels spe-
cific to cat and dog allergens at 29 days post-transplant (26). By
37 months post-transplant, exposure to cat and dog allergens trig-
gered asthma in the recipient. While the underlying mechanism
for this case is unknown, it does highlight and support the thesis
that hematopoietic cells are likely involved in the development of
allergic diseases.
There is an additional evidence for the contribution of HSPCs
in asthma that was presented by Doyle and colleagues (14). Here,
the authors demonstrated that mice challenged with ovalbumin
(OVA) resulted in amplification of hematopoietic stem cells in
the airway. Use of a CXCR4 antagonist attenuated hematopoietic
stem cell accumulation in the airway and was linked with decreased
AHR and airway remodeling (14). In humans, CD34+ progenitor
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cells were increased in the sputum of asthmatic patients following
exposure to inhaled allergen. This correlated well with angiogen-
esis in the bronchial mucosa (27). These findings indicate a role
for HSPCs in the inflammatory and remodeling components of
asthma.
There is large body of evidence to suggest that in the context of
allergic inflammation, HSPCs have increased migratory capabili-
ties. Stimulation of CD34+CD45+ cells with SDF-1α and eotaxin
increased migratory response in post-allergen stimulation com-
pared to pre-allergen levels. This was correlated with increased
expression of CXCR4 and CCR3 (15, 28). CCR3 expression on
CD34+ cells has been found to be upregulated in the presence
of interleukin-4 (IL-4) and IL-5 (16). SDF-1α, with the contri-
bution of Th2 cytokines, increased hematopoietic progenitor cells
homing to sites of allergic inflammation (8). SDF-1α is released in
the bronchoalveolar lavage (BAL) fluid and has been detected by
immunohistochemistry in endobronchial biopsies of asthmatics
(29). In asthma exacerbations, SDF-1α was found to be down-
regulated in the bone marrow and corresponded with increased
expression in asthmatic airways (30). Another chemokine, SCF,
was also found to be increased in the serum of non-severe and
severe asthmatics (31). Trafficking receptors expressed on HSPCs,
including CXCR4, CCR3, and c-kit, likely contribute to the migra-
tion of HSPCs to the sites of inflammation since serum from
asthmatics contain the chemoattractants, SDF-1α, eotaxin, and
SCF, respectively. In asthmatic lung, additional cytokines, includ-
ing granulocyte macrophage-colony stimulating factor (GM-CSF)
and growth factors, released by several cells, including T-helper
cells, are found. This suggests that inflammation during an aller-
gic event may promote HSPCs to the lungs, thereby contributing
to asthma pathophysiology (Figure 1).
Hematopoietic stem/progenitors have been demonstrated to
traffic to different tissues such as lung, liver, and kidney where
they reside for several days (17). The migration of HSPCs from
the bone marrow may depend on the peripheral environment.
CD34+ cells isolated from cord and peripheral blood showed
increased migratory response in the presence of IL-4. The priming
effect of cytokines was found to be through increased incorpora-
tion of the SDF-1α receptor CXCR4 into lipid rafts (8). VLA-4 on
bone marrow-derived CD34+45+ cells was found to be decreased
following allergen challenge. This may be a factor in facilitat-
ing movement of these cells out of the bone marrow and into
the peripheral circulation during an inflammatory response (32).
Indeed, release of SDF-1α and matrix metalloproteinase from the
bone does also occur (33). This suggests that while the cellular sig-
nals imposing HSPCs migration to the tissue are indeed similar,
changes in either the bone marrow, tissues, or both, dictate the
movement of HSPCs. Further studies are warranted to address the
parameters that determine when this occurs and what factors are
involved.
FIGURE 1 | Migration of hematopoietic progenitor cells into lung tissue: while the migration and diapedesis of hematopoietic stem/progenitor cells
are not completely understood, chemoattractants such as eotaxin, SCF, and SDF-1α can initiate HSPC migration to the site of inflammation in the
lung tissue.
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HSPC DIFFERENTIATION INTO EOSINOPHILS AND
BASOPHILS
Cytokines and growth factors exert their effects via binding to
specific receptors on the cell surface. Stem cell factor (SCF) and
IL-6 act early on in the survival and self-renewal of hematopoi-
etic stem cells, while other growth factors, such as IL-5, are largely
responsible for the terminal differentiation into eosinophils and
basophils (30).
Once within the lung, hematopoietic progenitor cells have the
potential to differentiate in situ. During asthma exacerbation, the
bone marrow is activated and HSPCs traffic to the lung. Cytokines
generated following allergen challenge can impact the differentia-
tion and mobilization of HSPCs leading to accelerated eosinophil
and basophil production, thus contributing to the ongoing recruit-
ment of pro-inflammatory cells to target tissues sites in allergic
diseases. Eosinophil and basophil progenitors are found to be
upregulated in peripheral blood, bone marrow, lung tissue, and
sputum in response to allergic stimuli, as a result of increased
differentiation and migration. The commitment of bone mar-
row progenitors to the eosinophil and basophil lineage has been
demonstrated to be regulated by pro-inflammatory cytokines,
including IL-3, IL-5, and GM-CSF, that are commonly found in
allergic tissue (30).
Increased eosinophil and basophil progenitors are found to be
correlated with increased acute respiratory symptoms in the cord
blood of infants (34). Assessment of eosinophil and basophil prog-
enitor cells in peripheral blood from children 1 year of age was
performed by using methylcellulose assays, which defines progeni-
tors on their ability to generate colony forming units (CFUs). IL-13
and GM-CSF-responsive eosinophil and basophil CFUs in the
blood of these children were found to be associated with exposure
to smoking related volatile organic compounds when exposed dur-
ing pregnancy or first year of life (35). This suggests that these cells
could respond to growth factors and cytokines at the site of inflam-
mation. In mice, Starkey and colleagues (36) found that Chlamydia
muridarum infection of infant mice had altered hematopoietic
cells with increased severity in airway hyperresponsiveness during
airway allergic disease in later life. Infant mice had increased IL-5
and IL-13 cytokines released from mediastinal lymph node cells
along with increased mucus secreting cells, increased transpul-
monary resistance, and IL-13 production in the lung (36). In
humans, stimulation of cord blood with lipopolysaccharide (LPS)
resulted in increased eosinophil and basophil progenitors. This
process was mediated by GM-CSF secretion by CD34+ cells and
required p38 mitogen-activated protein kinases (MAPK) activa-
tion (37). These studies further demonstrate the capability of
inflammatory events to initiate HPSC differentiation.
Epithelial cell-associated cytokines, such as IL-25 and IL-33,
have been suggested to be important in the initiation of aller-
gic responses. IL-25 has been shown to initiate Th2-type airway
inflammation but has also been shown to induce multipotent
progenitor cells into macrophages, basophils, and mast cells in
gut associated lymphoid tissue (2, 38). In IL-25−/− mice, IL-25
was produced by epithelial cells in OVA-challenged mice sug-
gesting that the allergic airway inflammation induced by OVA
challenge can initiate IL-25 expression (39). IL-33 was found to
be important in the differentiation of HSPCs into eosinophils.
IL-33 activity in the bone marrow compartment in mice acted
locally on hematopoietic progenitor cells in an IL-5-dependent
manner. IL-33 also triggered the production of IL-13 and IL-6,
and increased the production of CCL17 and transforming growth
factor-β (TGF-β) from wild-type eosinophils. In addition to dif-
ferentiation of hematopoietic progenitor cells into eosinophils,
IL-33 also increased lung levels of eosinophils, macrophages, lym-
phocytes, IL-13, TGF-β, CCL3, CCL17, and CCL24 in eosinophil-
mediated airway inflammation (40). CD34+ progenitor cells in
humans express a functional receptor for IL-33 that results in the
rapid release of high levels of cytokines and chemokines in the
presence of IL-33, further contributing to the possibility of IL-
33-mediated differentiation of progenitor cells (9). These studies
suggest the importance of IL-33 in mediating the differentiation
of HSPCs into eosinophils during an allergic event in the airways.
Despite these findings, careful investigations are required to con-
firm IL-25 involvement in HSPC differentiation. Further studies
looking at other epithelial cell-derived cytokines, such as TSLP,
should also be performed to further elucidate these mechanisms.
Bone marrow progenitors from inbred Rocky Mountain White
(IRW) mice were found to be incapable of proliferation or appro-
priate differentiation in response to SCF, Flt3-ligand (FLT3L), and
IL-5, which are the conditions defined for eosinophil differenti-
ation. Progenitors from IRW mice were also found to be unable
to differentiate into mast cells in the presence of IL-3 and SCF.
The authors found that while the progenitor cells were unable
to respond to factors ex vivo, OVA sensitization and challenge
resulted in eosinophilia. This suggests that there are other endoge-
nous compensatory mechanisms which drive differentiation, and
this requires further elucidation (19).
HSPC DIFFERENTIATION INTO MAST CELLS
The hematopoietic lineage for mast cell development is unique in
that mast cells leave the bone marrow as progenitors rather than as
circulating end-stage cells. Mast cell progenitors will accumulate
in different body tissues under the influence of locally produced
factors that determine the final phenotype of the mast cell. Mast
cell progenitors in the periphery, are identified by their expression
of FCεRI, c-Kit, CD13, CD33, CD34, CD38, and by their ability to
form granulated MC colonies in culture (41, 42).
In order to analyze the role of the bone marrow microenviron-
ment in human hematopoietic lineage development, a transgenic
mouse strain was developed that expressed human membrane-
bound SCF. CD34+ cells isolated from human cord blood were
then transplanted into NOD/SCID/IL2rgKO immunocompro-
mised mice that expressed membrane-bound SCF (hSCF Tg NSG).
These transgenic mice expressing human SCF had rapid expan-
sion of human CD45+ hematopoietic cells compared to non-
transgenic NSG recipients. Since SCF-c-Kit signaling is critical for
the maintenance of stem and progenitor cells, hSCF Tg NSG con-
tained mast cells in the lung cellular infiltrates. Membrane-bound
hSCF in the bone marrow resulted in enhanced development of
CD33+myeloid cells from the engrafted HSCs. Transgenic expres-
sion of human membrane-bound SCF influenced human myeloid
development and mast cell development in hematopoietic organs
and mucosal tissues along with the high chimerism of human
hematopoietic cells in hematopoietic organs (20). Al-Mushen and
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co-investigators (43) report the recovery of SCF mRNA-positive
cells from bronchial washings in allergic asthmatics at a higher
number compared to normal controls. While bronchial biopsy
showed that SCF expression was present primarily in the epithe-
lium, it was determined that alveolar macrophages were found to
be the major source of SCF in bronchial washings from asthmatic
subjects. Since the receptor for SCF, c-kit, is found on HSPCs and
not on monocytes, it is probable that these increased macrophages
are differentiated from circulating HSPCs (43).
RECRUITMENT OF MAST CELL PROGENITORS INTO TISSUES
In order for mast cell progenitors to migrate to the lung, they
must express α4β7 and α4β1 (VLA-4) integrins. These integrins
will bind to CXCR2-regulated VCAM-1 on endothelial cells. OVA
has been found to upregulate VCAM-1 expression suggesting that
mast cells further propagate inflammatory signals in the asthmatic
lung (44). There is evidence that mast cell recruitment into tissues
may also involve SCF binding to c-Kit, resulting in the activation of
the PI3K pathway. Thus it appears that SCF is a major chemotactic
factor for mast cells (42, 45).
Another chemokine involved in the attraction of mast cells to
the tissue is CCL2. In OVA-challenged mice, the levels of CCL2
and CXCL1 are increased in BAL fluid compared to non-sensitized
mice. In freshly isolated bone marrow, the functionality of the mast
cell progenitors to migrate to CCL2 was demonstrated in vitro
and further illustrated at the in vivo level by using subepithelial
irradiation and bone marrow adoptive transfer. Examination of
the bone marrows indicate that CCR2−/− OVA-challenged mice
reconstituted with WT bone marrow have a significant reduction
in the concentration of mast cell progenitors (46). This indicates
that CCR2/CCL2 signaling is imperative to the recruitment of
mast cell progenitors to the lung during antigen challenge and
that this requires participation of stromal and bone marrow ele-
ments. This study also denotes that CCL2 in the bone marrow
and CCR2 in the lung are important for mast cell progenitor
trafficking in the allergic airway models used and further high-
lights the complex signaling mechanisms in mast cell progenitor
trafficking.
HSPC DIFFERENTIATION INTO MONOCYTES/MACROPHAGES
Macrophages are terminally differentiated tissue dwelling cells
derived from circulating monocytes. Most tissue macrophages
are derived from hematopoietic stem cells and their local expan-
sion within tissues can be due to local proliferation of existing
macrophages or due to infiltration of blood-derived monocytes.
To fulfill many different roles in the tissue, macrophages can adapt
different phenotypes based on signals they receive from their envi-
ronment. Depending on their level of activation, macrophages can
differentiate into M1 or M2 cells. M1 macrophages act as pro-
inflammatory cells in host defense against intracellular pathogens
and cellular debris. M1 macrophages are induced by Th1 cytokines,
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), and
have been shown to be stimulated by GM-CSF and LPS. M2
macrophages are induced by Th2 cytokines, IL-4, and IL-13, and
also influenced by IL-10 and M-CSF. M2 macrophages produce
a wide range of factors that are involved in airway remodeling
that either lead to restoration of the tissue or pathological fibrosis
(47, 48 http://bloodjournal.hematologylibrary.org/content/79/4/
846.full.pdf ).
Monocytes/macrophages perform essential functions in home-
ostasis, infection, tissue repair, and resolution of inflammation.
These cells have pleiotropic functions in the body in that they
can interact with cells with progenitor or stem cell properties and
that this interplay may contribute to repair and remodeling (49,
50). Re-establishment of tissue homeostasis in response to injury
requires infiltration of inflammatory cells and activation of resi-
dent stem cells. Full tissue recovery requires that the inflammation
is resolved.
RECRUITMENT OF MONOCYTE/MACROPHAGE
PROGENITORS INTO TISSUES
The factors that influence monocyte/macrophage trafficking to
the lung during an inflammatory event are not well established.
However, in inflammatory disease states of other tissues such
as the liver, CCR2 activation on the surface of monocytes by
monocyte chemoattractant protein 1 (MCP-1) and MCP-3 fac-
tors at the site of inflammation may be responsible for the homing
of monocyte/macrophages to the area of injury (51). Therefore,
mechanisms of monocyte/macrophage migration during airway
inflammation deserve further attention.
There is evidence that both M1 and M2 cells are involved
in asthma. M2 macrophages have been found to correlate with
the severity of allergic airway inflammation in human and mice.
M1 macrophages have been suggested to be beneficial to pre-
vent allergic sensitization but may promote development of M2
macrophages in the presence of established disease (5). In OVA-
challenged mice, an increase in macrophages were recovered in
the BAL fluid following 1 week of OVA challenge, compared to
saline control mice. This increase in macrophages following aller-
gen challenge was also observed in macrophages recovered in the
tissues. While the number of macrophages in BAL decreased fol-
lowing weekly exposures to OVA, there was an increase in tissue
macrophages, further demonstrating macrophage involvement in
the pathogenesis of asthma (52).
Macrophage proliferation and activation requires MAPK.
MAPK activation requires phosphorylation on threonine and
tyrosine residues that are located in the activation loop. MAPK
activation are regulated by the dominant action of protein phos-
phatases, as evidenced by the fact that activation is reversible even
in the continued presence of activating stimuli. A key regulator of
macrophage proliferation and activation is mitogen-activated pro-
tein kinase phosphatase-1 (MKP-1). MKP-1 is a dual-specificity
phosphoprotein phosphatase and has been identified as a neg-
ative regulatory factor of the innate immune system and as a
key regulatory factor for macrophage proliferation and activation
(49). Expression of MKP-1 in tissue repair following damage was
demonstrated in muscle macrophages in which the tissue from
MKP−/− mouse lacked inflammatory cytokine expression despite
persistent tissue damage unveiling a function for macrophage con-
trolling stem cell dependent inflammation in damaged muscle
tissue repair (53). Regulation of innate immune inflammation
could thus be regulated by this phosphatase. Therefore, applica-
tion of therapeutics based on MKP-1 modulation could decrease
asthma morbidity and intensity.
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Signals released from M1 and M2 macrophages induced the
migration of meso-angioblasts in a chemotactic assay (54). The
results of this study support that macrophage recruit stem cells
to the site of injury in the tissue and the ability of precursor cells
to reconstitute the damaged tissue depends on the signals gener-
ated in situ by the macrophages. Therefore, intervention to allergic
disorders could be targeted in tempering stem cell migration by
modulating macrophage release of inflammatory cytokines. How-
ever, the origin of release of these chemoattractants is still poorly
characterized (54).
LYMPHOCYTES
Lymphocytes, such as T and B cells, differentiate from a com-
mon lymphoid progenitor and increased leukocyte progenitors
have been found in asthma patient blood (55). Th17 cells mediate
tissue inflammation and autoimmunity. TGF-β and IL-6 induce
Th17 differentiation from naïve CD4+ cells through regulation of
chromatin remodeling and IL-23 is required for expansion and
maintenance of Th17 cells. RORγt is considered to be a key tran-
scription factor for Th17 cells because its expression is induced
specifically during differentiation of Th17 cells by TGF and IL-6.
However, some cells that express RORγt function as T-regulatory
(Treg) cells. This raises the question of the role of RORγt in the
early differentiation process of T cells from HSC. In RORγt-BMT
mice where RORγt expression is forced at the HSC level, increased
expression of both Th17 and Treg expression was found. A series of
in vivo experiments in which HSCs expressing RORγt were trans-
planted into lethally irradiated mice, the effects of RORγt on T
cell development was evaluated. In contrast to mice transplanted
with HSCs expressing IL-17 which died within 14 days after trans-
plantation, those with reconstituted bone marrow hematopoiesis
survived without any autoimmune disorders during the observa-
tional period of over 16 weeks even though they had an increased
number of Th17 cells showing intracellular expression of IL-17.
Mice with increased number of Tregs had attenuated immune
response when challenged in a chronic hypersensitivity assay. This
phenomenon was supported with adoptive cell transfer of CD4+
T cells from these mice to recipient mice. Thus, these experiments
suggest that the surrounding cytokines, such as IL-5 and TGF-β,
influence the differentiation of Th17 to Treg cells by influencing
the expression of RORγt which ultimately results in decreased
tissue damage (56).
A protease responsible for cell migration and is highly expressed
in the asthmatic lung is a disintegrin and metalloprotease domain 8
(ADAM8). Adoptive transfer experiments showed that ADAM8 on
hematopoietic as well as on non-hematopoietic cells was required
for full asthmatic response, ADAM8-deficient T-lymphocytes sig-
nificantly decreased the asthmatic response. Thus, this enzyme
may also be a potential target for the inhibition of inflammatory
response in asthma (57).
FIBROCYTES
In addition to differentiation into eosinophils, basophils, and mast
cells, CD34+CD45+ cells can differentiate into several types of
tissue dwelling cells involved in the remodeling of the airway struc-
ture (9). Fibrocytes are thought to be derived from monocytes that
have similar features to that of fibroblasts and macrophages (58).
Fibrocytes express different fibroblast proteins such as vimentin,
collagen I and III, fibronectin, as well as CD34 and CD45 (59).
During the wound-healing process, the initially expressed CD34
will decrease with the induction of fibrocytes being induced
by TGF-β1 and endothelin-1 (ET-1). Evidence for fibrocytes in
asthma was observed in patients with chronic obstructive asthma.
Here, patients with chronic obstructive asthma compared with
asthmatic patients with normal pulmonary function and healthy
subjects had significant increase in the percentage of circulating
fibrocytes, as defined on the basis of expression of CD34+, CD45+,
and collagen I+ cells in non-adherent non-T cells (60).
Bone marrow-derived stem cells have been found to be respon-
sible for the proliferative cells in the asthmatic airway during
airway remodeling. In GFP+ bone marrow chimera mice, chronic
airway inflammation is characterized by increased thickness of
the airway subepithelial basement membrane and smooth muscle
layers. GFP+ bone marrow chimera cells produce collagen I and α-
smooth muscle actin in OVA-sensitized and challenged mice com-
pared to control mice (61). Bone marrow-derived fibrocytes was
further defined from fibroblasts isolated from cockroach antigen-
challenged mice. Cockroach antigen-challenged GFP+ bone mar-
row mice had increased fibroblasts in the lung compared to healthy
mice. Lung fibroblasts cells also express telomerase reverse tran-
scriptase (TERT), which is induced in lung injury and fibrosis.
The 70% of the TERT+ cells were found to be mostly derived
from bone marrow (62). Therefore, bone marrow-derived adult
stem cells can contribute to the increased fibroblast population
found in respiratory disease and are involved in the pathogenesis
of airway remodeling in asthma.
THERAPEUTIC CONSIDERATIONS
Given the involvement of hematopoietic progenitor cells in medi-
ating allergic inflammation and airway remodeling in asthma,
various molecules involved in the molecular process of the differ-
entiation of hematopoietic progenitor cells offer attractive ther-
apeutic targets in alleviating asthma. Therapies for asthma still
strongly rely on inhaled corticosteroids and long-acting inhaled β2
agonists. However, these treatments may not be able to fully reverse
the effects of inflammation and airway remodeling. Newer thera-
peutic approaches include treatment with IL-5 antibody. This was
found to decrease CD34+/IL-5Ra cells in atopic patients. Anti-IL-5
treatment may regulate local tissue infiltration of eosinophils (10,
63). However, so far this has not been found clinically successful.
Another target is the regulation of p38 MAPK. MKP-1 can
switch off p38 signaling and cytokine production in mono-
cytes/macrophages. This action was found to be increased in the
presence of vitamin D (64). This also gives further evidence in
offering vitamin D supplementation as a treatment option in vita-
min D. Reduced vitamin D levels are associated with impaired lung
function, increased AHR, and reduced glucocorticoid response.
MKP-1 was found to be increased in the lung with higher vitamin
D levels (65).
Oligonucleotides are an emerging family of drugs with poten-
tial to treat asthma. An inhaled anti-sense drug, TPI ASM8,
contains two modified phosphorothioate anti-sense oligonu-
cleotides (AON), one targeting the common beta chain (βc)
of the IL-3/IL-5/GM-CSF receptors and the other targeting
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FIGURE 2 | Differentiation of hematopoietic progenitor cells into immune cells: HSPCs can potentially differentiate into distinct immune cells in situ
depending on the presence of locally elevated factors and cytokines.
the chemokine receptor CCR3. Inhalation of TPI ASM8 sig-
nificantly improves lung function and sputum eosinophilia
after allergen inhalation challenge in mild asthmatic sub-
jects with early and late asthmatic responses. Thus, TPI
ASM8 may effectively block accumulation of eosinophils and
eosinophil progenitors in the airways following allergen chal-
lenge (66).
CONCLUSION
Allergic asthma is a complex disease characterized by chronic air-
way inflammation and increased airway hyperresponsiveness as
a reaction to allergen stimuli. There is evidence to support that
hematopoietic stem cell homing to the site of inflammation release
cytokines to influence and exacerbate allergic inflammation and
are also influenced by local cytokines and growth factors at the
site of injury. Their ability to differentiate in situ into differ-
ent immune cells is dependent on cytokine and growth factors
(Figure 2). Current investigative approaches looking at HSPCs dif-
ferentiation potential primarily focus on eosinophil and basophil
progenitors. However, important role of monocytes and mast cells
should not be overlooked and the potential for differentiation into
fibrocytes must also be considered. Future studies should address
the ability of HSPCs to differentiate in situ as well as focus on
factors that release HSPCs from the bone marrow and when this
occurs. Therefore, the management of hematopoietic progenitor
cells differentiation offers a potential therapeutic target. Therapy
that targets the maturation of CD34+ HSPCs specifically into the
inflammatory cells in the lung could result in reduced tissue mat-
uration of hematopoietic cells and thus decreased allergic airway
inflammation.
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